{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:26:12Z","timestamp":1781043972518,"version":"3.54.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Plan Nacional de Drogas","award":["2014-012"],"award-info":[{"award-number":["2014-012"]}]},{"name":"MINECO Plan Nacional I+D+i","award":["SAF-2015-65420R"],"award-info":[{"award-number":["SAF-2015-65420R"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/ijnp\/pyy049","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T11:19:05Z","timestamp":1527679145000},"page":"938-948","source":"Crossref","is-referenced-by-count":7,"title":["Sigma 1 Receptor Antagonists Inhibit Manic-Like Behaviors in Two Congenital Strains of Mice"],"prefix":"10.1093","volume":"21","author":[{"given":"Pilar","family":"S\u00e1nchez-Bl\u00e1zquez","sequence":"first","affiliation":[{"name":"Neuropharmacology, Department of Translational Neurosciences, Instituto Cajal, CSIC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Cort\u00e9s-Montero","sequence":"additional","affiliation":[{"name":"Neuropharmacology, Department of Translational Neurosciences, Instituto Cajal, CSIC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rodr\u00edguez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Neuropharmacology, Department of Translational Neurosciences, Instituto Cajal, CSIC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garz\u00f3n","sequence":"additional","affiliation":[{"name":"Neuropharmacology, Department of Translational Neurosciences, Instituto Cajal, CSIC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"key\n\t\t\t\t20181001010223_CIT0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archpsyc.55.1.27","article-title":"A factor analysis of the signs and symptoms of mania","volume":"55","author":"Cassidy","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0165-0327(98)00016-0","article-title":"Signs and symptoms of mania in pure and mixed episodes","volume":"50","author":"Cassidy","year":"1998","journal-title":"J Affect Disord"},{"key":"key\n\t\t\t\t20181001010223_CIT0003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pnpbp.2015.02.015","article-title":"Role of calcium, glutamate and NMDA in major depression and therapeutic application","volume":"64","author":"Deutschenbaur","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0004","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pharmthera.2010.04.003","article-title":"Sigma receptors: potential targets for a new class of antidepressant drug","volume":"127","author":"Fishback","year":"2010","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t20181001010223_CIT0005","first-page":"10","article-title":"Strain-specific battery of tests for domains of mania: effects of valproate, lithium and imipramine","volume":"1","author":"Flaisher-Grinberg","year":"2010","journal-title":"Front Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/2194-7511-1-20","article-title":"Glial-specific gene alterations associated with manic behaviors","volume":"1","author":"Gao","year":"2013","journal-title":"Int J Bipolar Disord"},{"key":"key\n\t\t\t\t20181001010223_CIT0007","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.neuropharm.2014.10.022","article-title":"HINT1 protein: a new therapeutic target to enhance opioid antinociception and block mechanical allodynia","volume":"89","author":"Garz\u00f3n","year":"2015","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t20181001010223_CIT0008","doi-asserted-by":"crossref","first-page":"43468","DOI":"10.1038\/srep43468","article-title":"Increased PKC activity and altered GSK3\u0392\/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces","volume":"7","author":"Garz\u00f3n-Ni\u00f1o","year":"2017","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20181001010223_CIT0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15622970902823202","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania","volume":"10","author":"Grunze","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0010","first-page":"243","article-title":"Factor structure of manic symptoms in adolescents","volume":"23","author":"Gupta","year":"2011","journal-title":"Ann Clin Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0011","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2011.04.047","article-title":"Modeling mania: further validation for Black Swiss mice as model animals","volume":"223","author":"Hannah-Poquette","year":"2011","journal-title":"Behav Brain Res"},{"key":"key\n\t\t\t\t20181001010223_CIT0012","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00023210-200418050-00001","article-title":"Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders","volume":"18","author":"Hayashi","year":"2004","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t20181001010223_CIT0013","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2174\/1389450110607011421","article-title":"Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions","volume":"7","author":"Jope","year":"2006","journal-title":"Curr Drug Targets"},{"key":"key\n\t\t\t\t20181001010223_CIT0014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FBP.0b013e32834f9e4e","article-title":"Behavioral differences in black Swiss mice from separate colonies: implications for modeling domains of mania","volume":"23","author":"Juetten","year":"2012","journal-title":"Behav Pharmacol"},{"key":"key\n\t\t\t\t20181001010223_CIT0015","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1017\/S1461145710001495","article-title":"Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania","volume":"14","author":"Kalinichev","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20181001010223_CIT0016","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.tins.2012.09.007","article-title":"The sigma-1 receptor: roles in neuronal plasticity and disease","volume":"35","author":"Kourrich","year":"2012","journal-title":"Trends Neurosci"},{"key":"key\n\t\t\t\t20181001010223_CIT0017","first-page":"237","article-title":"Mania following ketamine abuse","volume":"12","author":"Lu","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"key\n\t\t\t\t20181001010223_CIT0018","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0006-3223(99)00235-8","article-title":"Ziskind-somerfeld research award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness","volume":"46","author":"Manji","year":"1999","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0019","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1113\/jphysiol.2006.116178","article-title":"The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus","volume":"578","author":"Martina","year":"2007","journal-title":"J Physiol"},{"key":"key\n\t\t\t\t20181001010223_CIT0020","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2165\/11633130-000000000-00000","article-title":"Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date","volume":"72","author":"Mathews","year":"2012","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20181001010223_CIT0021","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1755-5949.2010.00178.x","article-title":"Downregulation and upregulation of glial connexins may cause synaptic imbalances responsible for the pathophysiology of bipolar disorder","volume":"17","author":"Mitterauer","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"key\n\t\t\t\t20181001010223_CIT0022","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jad.2013.11.014","article-title":"A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action","volume":"156","author":"Naughton","year":"2014","journal-title":"J Affect Disord"},{"key":"key\n\t\t\t\t20181001010223_CIT0023","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1523\/JNEUROSCI.4753-03.2004","article-title":"Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium","volume":"24","author":"O\u2019Brien","year":"2004","journal-title":"J Neurosci"},{"key":"key\n\t\t\t\t20181001010223_CIT0024","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.biopsych.2008.05.014","article-title":"Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania","volume":"64","author":"Ong\u00fcr","year":"2008","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.psychres.2010.04.032","article-title":"Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm","volume":"178","author":"Perry","year":"2010","journal-title":"Psychiatry Res"},{"key":"key\n\t\t\t\t20181001010223_CIT0026","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/mp.2013.136","article-title":"Imaging glutamate in schizophrenia: review of findings and implications for drug discovery","volume":"19","author":"Poels","year":"2014","journal-title":"Mol Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0027","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/npp.2010.43","article-title":"Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances","volume":"35","author":"Polter","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20181001010223_CIT0028","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"key\n\t\t\t\t20181001010223_CIT0029","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0006-3223(00)00950-1","article-title":"Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells","volume":"48","author":"Rajkowska","year":"2000","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20181001010223_CIT0030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/npp.2011.155","article-title":"The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control","volume":"37","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20181001010223_CIT0031","doi-asserted-by":"crossref","first-page":"35458","DOI":"10.18632\/oncotarget.6064","article-title":"The ON:OFF switch, \u03c31r-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders","volume":"6","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2015","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t20181001010223_CIT0032","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1089\/ars.2014.5993","article-title":"The \u03c31 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control","volume":"22","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"key\n\t\t\t\t20181001010223_CIT0033","doi-asserted-by":"crossref","first-page":"55840","DOI":"10.18632\/oncotarget.10095","article-title":"Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction","volume":"7","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2016","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t20181001010223_CIT0034","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1124\/mol.112.083352","article-title":"Ionotropic glutamate receptors: regulation by G-protein-coupled receptors","volume":"83","author":"Rojas","year":"2013","journal-title":"Mol Pharmacol"},{"key":"key\n\t\t\t\t20181001010223_CIT0035","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1007\/s12035-017-0697-x","article-title":"The sigma-1 receptor antagonist, S1RA, reduces stroke damage, ameliorates post-stroke neurological deficits and suppresses the overexpression of MMP-9","volume":"55","author":"S\u00e1nchez-Bl\u00e1zquez","year":"2018","journal-title":"Mol Neurobiol"},{"key":"key\n\t\t\t\t20181001010223_CIT0036","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1089\/ars.2012.5100","article-title":"Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate","volume":"19","author":"S\u00e1nchez-Bl\u00e1zquez","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"key\n\t\t\t\t20181001010223_CIT0037","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1017\/S1461145714000029","article-title":"The calcium-sensitive sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases","volume":"17","author":"S\u00e1nchez-Bl\u00e1zquez","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20181001010223_CIT0038","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1399-5618.2005.00203.x","article-title":"Neuropsychological dysfunction in bipolar affective disorder: a critical opinion","volume":"7","author":"Savitz","year":"2005","journal-title":"Bipolar Disord"},{"key":"key\n\t\t\t\t20181001010223_CIT0039","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.neuroscience.2009.04.013","article-title":"Glutamate-mediated calcium signaling: a potential target for lithium action","volume":"161","author":"Sourial-Bassillious","year":"2009","journal-title":"Neuroscience"},{"key":"key\n\t\t\t\t20181001010223_CIT0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuropharm.2008.08.015","article-title":"Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania","volume":"56","author":"Szabo","year":"2009","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t20181001010223_CIT0041","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1517\/13543784.2015.1048334","article-title":"Investigational sigma-1 receptor antagonists for the treatment of pain","volume":"24","author":"Vela","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t20181001010223_CIT0042","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.euroneuro.2007.02.007","article-title":"Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice","volume":"17","author":"Wang","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20181001010223_CIT0043","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1476-5381.2011.01318.x","article-title":"Predictive animal models of mania: hits, misses and future directions","volume":"164","author":"Young","year":"2011","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20181001010223_CIT0044","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2165\/00023210-200923070-00003","article-title":"Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder","volume":"23","author":"Zarate","year":"2009","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t20181001010223_CIT0045","doi-asserted-by":"crossref","first-page":"12211","DOI":"10.1523\/JNEUROSCI.3321-07.2007","article-title":"Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments","volume":"27","author":"Zhu","year":"2007","journal-title":"J Neurosci"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/21\/10\/938\/25863736\/pyy049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T20:40:54Z","timestamp":1571431254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/21\/10\/938\/5026116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,5,31]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyy049","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,5,31]]}}}